Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
作者： Michael D. Prados , W. K. A. Yung , Patrick Y. Wen , Larry Junck , Timothy Cloughesy
DOI: 10.1007/S00280-007-0556-Y
关键词:
摘要: Purpose This is a phase-I study of gefitinib in combination with temozolomide patients gliomas. The goal the was to define maximum tolerated dose (MTD) and characterize pharmacokinetics when combined temozolomide.
springer.com
sci-hub.se 参考文章(20)
F Cappuzzo, C Calandri, S Bartolini, L Crinò, ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. British Journal of Cancer. ,vol. 89, pp. 246- 247 ,(2003) , 10.1038/SJ.BJC.6601116
Baldassarre Stea, Ryan Falsey, Kerri Kislin, Jay Patel, Heather Glanzberg, Steven Carey, Aaron A. Ambrad, Emmanuelle J. Meuillet, Jesse D. Martinez, Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa') Cancer Letters. ,vol. 202, pp. 43- 51 ,(2003) , 10.1016/J.CANLET.2003.07.006
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
H.K Jones, L.E Stafford, H.C Swaisland, R Payne, A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. Journal of Pharmaceutical and Biomedical Analysis. ,vol. 29, pp. 221- 228 ,(2002) , 10.1016/S0731-7085(02)00014-6
Takeshi Kitazaki, Mikio Oka, Yoichi Nakamura, Junji Tsurutani, Seiji Doi, Masa Yasunaga, Masaaki Takemura, Hikaru Yabuuchi, Hiroshi Soda, Shigeru Kohno, Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells Lung Cancer. ,vol. 49, pp. 337- 343 ,(2005) , 10.1016/J.LUNGCAN.2005.03.035
Arnab Chakravarti, Adam Dicker, Minesh Mehta, The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. International Journal of Radiation Oncology Biology Physics. ,vol. 58, pp. 927- 931 ,(2004) , 10.1016/J.IJROBP.2003.09.092
David J. Begley, Delivery of therapeutic agents to the central nervous system: the problems and the possibilities Pharmacology & Therapeutics. ,vol. 104, pp. 29- 45 ,(2004) , 10.1016/J.PHARMTHERA.2004.08.001
Roger Stupp, Warren P. Mason, Martin J. van den Bent, Michael Weller, Barbara Fisher, Martin J.B. Taphoorn, Karl Belanger, Alba A. Brandes, Christine Marosi, Ulrich Bogdahn, Jürgen Curschmann, Robert C. Janzer, Samuel K. Ludwin, Thierry Gorlia, Anouk Allgeier, Denis Lacombe, J. Gregory Cairncross, Elizabeth Eisenhauer, René O. Mirimanoff, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma The New England Journal of Medicine. ,vol. 352, pp. 987- 996 ,(2005) , 10.1056/NEJMOA043330
Bert Vogelstein, Darell D. Bigner, Joachim Mark, Albert J. Wong, Henry S. Friedman, Sandra H. Bigner, Peter A. Humphrey, Characterization of the Epidermal Growth Factor Receptor in Human Glioma Cell Lines and Xenografts Cancer Research. ,vol. 50, pp. 8017- 8022 ,(1990)
Michael D. Prados, Kathleen R. Lamborn, Susan Chang, Eric Burton, Nicholas Butowski, Mary Malec, Ami Kapadia, Jane Rabbitt, Margaretta S. Page, Ann Fedoroff, Dong Xie, Sean K. Kelley, Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncology. ,vol. 8, pp. 67- 78 ,(2006) , 10.1215/S1522851705000451